7 research outputs found
Conservation Strategy for Brown Bear and Its Habitat in Nepal
The Himalaya region of Nepal encompasses significant habitats for several endangered species, among them the brown bear (Ursus arctos pruinosus). However, owing to the remoteness of the region and a dearth of research, knowledge on the conservation status, habitat and population size of this species is lacking. Our aim in this paper is to report a habitat survey designed to assess the distribution and habitat characteristics of the brown bear in the Nepalese Himalaya, and to summarize a conservation action plan for the species devised at a pair of recent workshops held in Nepal. Results of our survey showed that brown bear were potentially distributed between 3800 m and 5500 m in the high mountainous region of Nepal, across an area of 4037 km2 between the eastern border of Shey Phoksundo National Park (SPNP) and the Manasalu Conservation Area (MCA). Of that area, 2066 km2 lie inside the protected area (350 km2 in the MCA; 1716 km2 in the Annapurna Conservation Area) and 48% (1917 km2) lies outside the protected area in the Dolpa district. Furthermore, 37% of brown bear habitat also forms a potential habitat for blue sheep (or bharal, Pseudois nayaur), and 17% of these habitats is used by livestock, suggesting a significant potential for resource competition. Several plant species continue to be uprooted by local people for fuel wood. Based on the results of our field survey combined with consultations with local communities and scientists, we propose that government and non-government organizations should implement a three-stage program of conservation activities for the brown bear. This program should: (a) Detail research activities in and outside the protected area of Nepal; (b) support livelihood and conservation awareness at local and national levels; and (c) strengthen local capacity and reduce human-wildlife conflict in the region
Assessing mammal distribution and abundance in intricate eastern Himalayan habitats of Khangchendzonga, Sikkim, India
Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4′-thio-2′-deoxycytidine and 5-aza-4′-thio-2′-deoxycytidine
Recommended from our members
Age of Onset and Disease Course in Biopsy-Proven Minimal Change Disease: An Analysis From the Cure Glomerulopathy Network
Recommended from our members
Association of COVID-19 Versus COVID-19 Vaccination With Kidney Function and Disease Activity in Primary Glomerular Disease: A Report of the Cure Glomerulonephropathy Study
Patients with glomerular disease (GN) may be at increased risk of severe COVID-19, yet concerns over vaccines causing disease relapse may lead to vaccine hesitancy. We examined the associations of COVID-19 with longitudinal kidney function and proteinuria and compared these to similar associations with COVID-19 vaccination.
Observational cohort study from July 1, 2021 to Jan. 1, 2023.
& Participants: A prospective observational study network of 71 centers from North America and Europe (CureGN) with children and adults with primary minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy.
COVID-19 and COVID-19 vaccination.
Repeated measure of estimated glomerular filtration rate (eGFR); recurrent time-to-event outcome of GN disease worsening as defined by doubling of UPCR to at least 1.5g/g or increase in dipstick urine protein by two ordinal levels to 3+ (300mg/dL) or above.
Interrupted time series analysis for eGFR. Prognostic matched sequential stratification recurrent event analysis for GN disease worsening.
Among 2,055 participants, 722 (35%) reported COVID-19; of these, 92 (13%) were hospitalized and 3 died (<1%). eGFR slope pre-COVID-19 was -1.40ml/min/1.73m2 (SD 0.29), and -4.26ml/min/1.73m2 (SD 3.02) within 6 months post-COVID-19, which were not significantly different (p=0.34). COVID-19 was associated with increased risk of worsening GN disease activity (HR 1.35, 95% CI 1.01-1.80). Vaccination was not associated with change in eGFR (-1.34ml/min/1.73m2, SD 0.15 vs -2.16ml/min/1.73m2, SD 1.74; p=0.6) or subsequent GN disease worsening (HR 1.02, 95% CI 0.79–1.33) in this cohort.
Infrequent or short follow-up.
Among patients with primary GN, COVID-19 was severe for 1 in 8 cases and was associated with subsequent worsening of GN disease activity, as defined by proteinuria. In contrast, vaccination against COVID-19 was not associated with change in disease activity or kidney function decline. These results support COVID-19 vaccination for patients with GN.
In this cohort study of 2,055 patients with minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy, COVID-19 resulted in hospitalization or death for 1 in 8 cases and was associated with a 35% increase in risk for worsening proteinuria. In contrast, vaccination did not appear to adversely affect kidney function or proteinuria. Our data support vaccination for COVID-19 in patients with glomerular disease